share_log

The Flowr Corporation Announces First Quarter 2022 Results and Reinstatement of Trading

The Flowr Corporation Announces First Quarter 2022 Results and Reinstatement of Trading

Flowr公司宣布2022年第一季度业绩和恢复交易
GlobeNewswire ·  2022/05/30 20:01

Highlights:

重点:

  • In Q1 2022, the Company generated gross revenue of $3.9 million as a result of the sale of 1,179,735 grams of dried cannabis flower, an increase of 75% compared to Q1, 2021
  • Net loss decreased by $2.2 million in Q1, 2022 or 26% to a loss of $6.1 million compared to Q1, 2021
  • SG&A expenses in Q1 2022 were $2.9 million, or 29% lower than Q1, 2021
  • 2022年第一季度,该公司销售了1,179,735克干大麻花,毛收入为390万美元,较2021年第一季度增长75%
  • 与2021年第一季度相比,2022年第一季度净亏损减少220万美元,降幅26%,至亏损610万美元
  • 2022年第一季度的SG&A费用为290万美元,比2021年第一季度下降29%

Key Subsequent Events:

后续关键事件:

  • During Q2, the Company paid $1.6 million from the Holigen sale towards the repayment of the ATB Term Facility upon closing of the transaction.
  • 在第二季度,该公司从Holigen出售中支付了160万美元,用于在交易完成时偿还ATB定期贷款。

TORONTO, May 30, 2022 (GLOBE NEWSWIRE) -- The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) ("Flowr" or the "Company") herein announces its financial and operational results for the first quarter results for the period ended March 31, 2022.   All financial information in this news release is reported in thousands ('$000s) of Canadian dollars and represents results from continuing operations, unless otherwise indicated.

多伦多,2022年5月30日(环球社)--The Flowr Corporation(多伦多证券交易所股票代码:FLWR;场外交易代码:FLWPF)(““或”公司“)在此宣布其截至2022年3月31日的第一季度的财务和运营业绩。本新闻稿中的所有财务信息都以数千加元(‘000美元)报告,除非另有说明,否则代表持续运营的结果。

Tom Flow, Interim Chief Executive Officer of Flowr, commented:

Flowr临时首席执行官Tom Flow评论道:

"The first quarter of 2022 showed that we remain on track with our objective on maintaining our status as a premium cannabis producer. Also, our continued focus on cost reductions is showing in our bottom-line improvements."

2022年第一季度表明,我们仍在实现保持优质大麻生产商地位的目标。此外,我们继续专注于降低成本,这体现在我们的底线改善上。

SELECTED FINANCIAL AND OPERATIONAL RESULTS

精选财务和运营结果

The following table summarizes the Company's key financial and operational results:

下表汇总了该公司的主要财务和经营业绩:

In thousands of CAD dollars,   Three months ended
 
(except loss per share and grams harvested)   March 31,
 
    2022     2021  
Grams harvested - K1   1,232,654     669,307  
Grams sold   1,179,735     672,566  
Gross revenue   3,878     4,403  
Net revenue   3,463     3,622  
Cost of sales   3,678     2,730  
Impairment of inventory   683     749  
Gross profit/(loss) before fair value adjustments   (898 )   143  
Selling and marketing and G&A   2,852     3,999  
Share-based compensation   (225 )   421  
Impairment of assets   29      
Loss/(gain) from disposal of subsidiary       (54 )
Net loss   (5,762 )   (7,081 )
Basic and diluted loss per share   (0.01 )   (0.02 )
以数千加元计, 截至三个月
(每股亏损和收获的克数除外) 3月31日,
2022 2021
收获的克数-K1 1,232,654 669,307
售出的克数 1,179,735 672,566
毛收入 3,878 4,403
净收入 3,463 3,622
销售成本 3,678 2,730
存货减值 683 749
公允价值调整前毛利/(亏损) (898 ) 143
销售、市场营销和并购 2,852 3,999
基于股份的薪酬 (225 ) 421
资产减值 29
出售子公司的亏损/(收益) (54 )
净亏损 (5,762 ) (7,081 )
每股基本亏损和摊薄亏损 (0.01 ) (0.02 )

Financial Results (presented in $000s)

财务业绩(以2000美元为单位)

  • Gross revenue for Q1 2022 was $3,878 compared to $4,403 in Q1 2021, a decline of $525 or 12%. Net revenue during Q1 2022 was $3,463, $159 or 4% lower than Q1 2021. The decrease in revenue is primarily a result of a lower average net sale price, partially offset by higher volume. Sale of retail products during Q1 2022 was 257 kilograms compared with 541 kilograms in Q1 2021. Sale of cannabis through bulk wholesale channels during Q1 2022 was 923 kilograms compared to 131 kilograms in Q1 2021 primarily due to higher production from the K1 facility.
  • SG&A expenses for Q1 2022 was $2,852 compared with $3,999 in Q1 2021, a decrease of $1,147 or 29% primarily as a result cost reduction measures the Company implemented that began 2021 and continued in 2022.
  • Gross loss for Q1 2022 was $898 compared with a profit of $143 for Q1 2021 primarily as a result a lower profit margin on products sold.
  • Cost of sales for Q1 2022 was $3,678 compared to $2,730 for Q1 2021. The increase in cost of sales resulted from a significantly higher volume of cannabis sold during the current quarter at 1,180 kilograms compared with 673 kilograms sold during Q1 2021.
  • The Company recorded impairment charges totaling $29 in Q1 2022 compared with $nil in Q1 2021.
  • Net loss of the Company totaled $5,762 for Q1 2022 compared to a loss of $7,081 for Q1 2021. The change in net loss was primarily due to a higher gross loss more than offset by lower SG&A, a reversal in share-based compensation, lower depreciation and finance costs.
  • 与2021年第一季度的4,403美元相比,2022年第一季度的毛收入为3,878美元,下降了525美元或12%。2022年第一季度的净收入为3,463美元,比2021年第一季度下降159美元或4%。收入的减少主要是由于平均净销售价格下降,但部分被较高的销量所抵消。2022年第一季度零售产品销售额为257公斤,而2021年第一季度为541公斤。2022年第一季度通过大宗批发渠道销售的大麻为923公斤,而2021年第一季度为131公斤,这主要是由于K1工厂的产量增加。
  • 与2021年第一季度的3,999美元相比,2022年第一季度的SG&A费用为2,852美元,减少了1,147美元或29%,这主要是由于公司从2021年开始实施并于2022年继续实施的成本削减措施。
  • 2022年第一季度的总亏损为898美元,而2021年第一季度的利润为143美元,这主要是由于销售产品的利润率较低。
  • 2022年第一季度的销售成本为3678美元,而2021年第一季度的销售成本为2730美元。销售成本的增加是因为本季度的大麻销售量大幅增加,为1180公斤,而2021年第一季度的销售量为673公斤。
  • 本公司于2022年第一季度记录的减值费用总额为29美元,而2021年第一季度的减值费用为零。
  • 2022年第一季度,公司净亏损总额为5,762美元,而2021年第一季度亏损为7,081美元。净亏损的变化主要是由于较高的总亏损被较低的SG&A、以股份为基础的薪酬逆转、较低的折旧和融资成本所抵消。

Operational Updates

运营更新

  • Q1 2022, Flowr continued full operation in all 20 grow rooms at the K1 facility and improved the THC level by an average of +4.9% in comparison to Q1 2021. 
  • Q1 2022 harvest yield was 84% higher than Q1 2021 (1,232,654 grams vs 669, 307 grams).  
  • Flowr has further increased its product offerings in Q1 2022 with the launch of BC Vanilla Frost and BC Tropical Zktlz in Quebec, BC Clementine Crush into British Columbia, and BC Strawnana in Alberta. 
  • In Q1 2022 Flowr continued to trial more than 50 new genetic strains to offer consumers differentiated exotic genetics, with high THC, high terpene contents, strong sensory profiles and premium quality buds.  
  • The Company has made significant steps to improve product quality in Q1 2022, by adding a processing step to sort buds post-harvest, as well as adding moisture control packs to bulk and retail products. 
  • The Company has shown significant growth in retail penetration across its core markets of Ontario, Alberta and British Columbia with more than 60% of stores carrying a Flowr product. 
  • 2022年第一季度,Flowr继续在K1设施的所有20个种植室全面运营,与2021年第一季度相比,THC水平平均提高了+4.9%。
  • 2022年第一季度的收获产量比2021年第一季度(1,232,654克对669,307克)高出84%。
  • Flowr在2022年第一季度进一步增加了产品供应,在魁北克推出了BC Vanilla Frost和BC Tropical Zktlz,在不列颠哥伦比亚省推出了BC Clementine Crush,在艾伯塔省推出了BC Strawnana。
  • 2022年第一季度,Flowr继续试验50多个新的遗传菌株,为消费者提供差异化的外来遗传学,具有高THC、高萜类含量、强烈的感官特征和优质的芽。
  • 该公司在2022年第一季度采取了重大措施来提高产品质量,增加了采摘后分拣花蕾的处理步骤,并在散装和零售产品中增加了水分控制包装。
  • 该公司在安大略省、艾伯塔省和不列颠哥伦比亚省等核心市场的零售渗透率出现了显著增长,超过60%的商店销售Flowr产品。

Adjusted EBITDA (Non-IFRS Measure)

调整后的EBITDA(非国际财务报告准则计量)

Adjusted EBITDA is defined as net loss, plus (minus) income taxes (recovery), plus (minus) interest income (expense) including finance costs, plus depreciation and amortization, plus share-based compensation, plus (minus) non-cash fair value adjustments on biological assets and inventory sold, plus restructuring and transaction costs, plus (minus) loss (gain) on investments, plus impairment charges, and plus (minus) unusual or non-recurring items. Management believes this measure provides useful information as it is a commonly used measure in the capital markets and as it is a close proxy for repeatable cash used by operations.

调整后的EBITDA定义为净亏损加上(减去)所得税(回收),加上(减去)包括财务成本的利息收入(支出),加上折旧和摊销,加上基于股票的薪酬,加上(减去)出售的生物资产和存货的非现金公允价值调整,加上重组和交易成本,加上(减去)投资损失(收益),加上减值费用,加上(减去)异常或非经常性项目。管理层认为,这一衡量标准提供了有用的信息,因为它是资本市场常用的衡量标准,也是业务活动使用的可重复现金的密切代表。

For a full discussion of Flowr's operational and financial results for the year ended December 31, 2021, please refer to the Company's Management's Discussion & Analysis and Consolidated Financial Statements for the year ended December 31, 2021, which have been filed on SEDAR.

有关Flowr截至2021年12月31日的年度的经营和财务业绩的全面讨论,请参阅已在SEDAR上提交的公司管理层截至2021年12月31日的年度的讨论与分析和综合财务报表。

Reinstatement of Trading

恢复营业

The Company is pleased to announce that the failure-to-file cease trade order issued by the Ontario Securities Commission on May 6, 2022 ("FFCTO") against the Company has been fully revoked by the applicable regulatory authorities.

本公司欣然宣布,安大略省证券事务监察委员会于2022年5月6日发出的未能提交停止交易令(“FFCTO“)已被适用的监管当局完全撤销。

The FFCTO was issued as a result of the Company's failure to file the following periodic disclosure documents (the "Annual Filings") by the filing deadline of May 2, 2022:

FFCTO的发布是由于公司未能提交以下定期披露文件(“年度提交文件“)在2022年5月2日的提交截止日期前:

  • the audited annual financial statements of the Company for the year ended December 31, 2021;
  • the management's discussion and analysis of the Company for the year ended December 31, 2021; and
  • certificates of each of the Interim Chief Executive Officer and the Chief Financial Officer relating to the audited annual financial statements.
  • 本公司截至2021年12月31日的经审计年度财务报表;
  • 管理层对本公司截至2021年12月31日止年度的讨论及分析;及
  • 临时首席执行官和首席财务官关于经审计的年度财务报表的证书。

The Annual Filings were filed on SEDAR on May 20, 2022.

年报于2022年5月20日在SEDAR上提交。

As previously announced on May 11, 2022, effective May 6, 2022, the TSX Venture Exchange ("TSXV") suspended trading in the Company's securities as a result of the issuance of the FFCTO. The Company applied to the TSXV for the reinstatement of trading of the Company's securities on the TSXV. The reinstatement of trading of the Company's securities on the TSXV was granted by the TSXV on May 27, 2022 and the common shares of Flowr will be reinstated to trade effective at the opening on May 31, 2022.

正如此前于2022年5月11日宣布的那样,自2022年5月6日起,多伦多证券交易所创业板(TSX)TSXV“)因FFCTO发行而暂停本公司证券的交易。本公司向多伦多证券交易所申请恢复本公司证券在多伦多证券交易所的交易。于2022年5月27日,多伦多证券交易所批准恢复本公司证券在多伦多证券交易所的交易,Flowr的普通股将于2022年5月31日开盘时恢复交易。

In addition, further to the Company's press release dated May 2, 2022 in respect of the completion of the sale of Holigen Holdings (the "Holigen Sale"), an arm's length third party received a cash payment of C$1,250,478.72 and 96,354 common shares of Akanda Corp. as an advisory fee in connection with the services provided to the Company in relation to the Holigen Sale.

此外,继本公司于2022年5月2日就完成出售Holigen Holdings(“Holigen大甩卖“),一名公平第三方收到1,250,478.72加元和96,354股Akanda Corp.普通股的现金付款,作为与向本公司提供与Holigen出售有关的服务有关的咨询费。

About The Flowr Corporation

关于Flowr公司

The Flowr Corporation is a Canadian cannabis company with its operating campus located in Kelowna, British Columbia. Flowr aims to support improving outcomes through responsible cannabis use and, as an established expert in cannabis cultivation, strives to be the brand of choice for consumers and patients seeking the highest-quality craftsmanship and product consistency across a portfolio of differentiated cannabis products.  

The Flowr Corporation是一家加拿大大麻公司,其运营园区位于不列颠哥伦比亚省基洛纳。Flowr的目标是通过负责任的大麻使用来支持改善结果,作为大麻种植方面的知名专家,Flowr努力成为消费者和患者的首选品牌,他们希望通过一系列差异化的大麻产品组合获得最高质量的工艺和产品一致性。

For more information, please visit flowrcorp.com or follow Flowr on Twitter: @FlowrCanada and LinkedIn: The Flowr Corporation.

欲了解更多信息,请访问Flowrcorp.com或在推特上关注Flowr:@FlowrCanada和LinkedIn:The Flowr Corporation。

On behalf of The Flowr Corporation:

我代表Flowr公司:

Tom Flow
Interim Chief Executive Officer

TOM流
临时行政总裁

CONTACT INFORMATION:

联系方式:

INVESTORS & MEDIA:
investors@flowrcorp.com

投资者和媒体:
邮箱:Investors@flow rcorp.com

Forward-Looking Information:

前瞻性信息:

Certain statements made in this press release may constitute "forward-looking information", "future oriented financial information" or "financial outlooks" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information may relate to anticipated events or results including, but not limited to: the Company's expectation that it will build on its achievements as it continues to invest in sales and marketing; the Company's expectations for sales of product in Quebec; Flowr's business, production and products; Flowr's plans to provide premium quality cannabis to adult use recreational and medical markets; EU-GMP certification opening the medicinal cannabis opportunity for the Company in global markets; the Company being well positioned to distribute EU-GMP compliant product into underserviced markets; the Company's ability to obtain licensing from Health Canada and other regulatory authorities with respect to its properties and facilities; future legislative and regulatory developments in Canada and elsewhere; the cannabis industry in Canada generally; the ability of Flowr to implement its business strategies; and the ability of Flowr to produce or sell premium quality cannabis. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Often, but not always, forward-looking statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "believe", "estimate", "plan", "could", "should", "would", "outlook", "forecast", "anticipate", "foresee", "continue" or the negative of these terms or variations of them or similar terminology. Forward-looking information is current as of the date it is made and is based on reasonable estimates and assumptions made by us at the relevant time in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. To the extent any forward-looking information in this press release constitutes "future oriented financial information" or "financial outlooks", within the meaning of applicable securities laws, the purpose of such information being provided is to demonstrate the potential of the Company and readers are cautioned that this information may not be appropriate for any other purpose. However, we do not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. There can be no assurance that such estimates and assumptions will prove to be correct. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking information as discussed in the Company's other publicly filed documents, which can be accessed under the Company's profile on the System for Electronic Document Analysis and Retrieval ("SEDAR") at . The Company cautions that the list of risk factors and uncertainties described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

本新闻稿中的某些陈述可能构成“前瞻性信息”、“面向未来的财务信息”或“财务展望”(统称为“前瞻性信息“)在适用的证券法的含义内。前瞻性信息可能与预期的事件或结果有关,这些事件或结果包括但不限于:公司在继续投资于销售和营销的同时将在其成就的基础上再接再厉的期望;公司对魁北克产品销售的期望;Flowr的业务、生产和产品;Flowr向成人娱乐和医疗市场提供优质大麻的计划;EU-GMP认证为公司在全球市场打开医用大麻的机会;公司能够很好地向服务不足的市场销售符合EU-GMP的产品;该公司获得加拿大卫生部和其他监管机构对其物业和设施的许可的能力;加拿大和其他地方未来的立法和监管发展;加拿大大麻行业的总体情况;Flowr实施其商业战略的能力;以及Flowr生产或销售优质大麻的能力。具体地说,有关我们对未来结果、目标、业绩成就、前景或机会的预期的信息是前瞻性信息。前瞻性陈述常常但并非总是可以通过使用前瞻性术语来识别,如“可能”、“将”、“预期”、“相信”、“估计”、“计划”、“可能”、“应该”、“将”、“展望”、“预测”、“预期”、“预见”、“继续”或这些术语的否定或它们的变体或类似术语。前瞻性信息是截至发布之日的最新信息,基于我们在相关时间根据我们对历史趋势、当前状况和预期未来发展的经验和看法做出的合理估计和假设。, 以及我们认为在这种情况下适当和合理的其他因素。如果本新闻稿中的任何前瞻性信息构成适用证券法所指的“面向未来的财务信息”或“财务展望”,则提供此类信息的目的是展示公司的潜力,请读者注意,此类信息可能不适用于任何其他目的。然而,我们不承诺因新信息、未来事件或其他原因而更新任何此类前瞻性信息,除非加拿大适用的证券法要求。不能保证这样的估计和假设将被证明是正确的。许多因素可能会导致我们的实际结果、活动水平、业绩或成就或未来的事件或发展与公司其他公开申报文件中讨论的前瞻性信息所表达或暗示的内容存在实质性差异。这些前瞻性信息可根据公司在电子文件分析和检索系统上的简介(“SEDAR“)。公司提醒,AIF中描述的风险因素和不确定因素并非详尽无遗,其他因素也可能对其结果产生不利影响。请读者在评估前瞻性信息时仔细考虑风险、不确定因素和假设,并告诫不要过度依赖这些信息。

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多伦多证券交易所风险交易所及其监管服务提供商(该术语在多伦多证券交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发